30/05/2019 – AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET
28/05/2019 – AB Science announces the lifting of the ANSM clinical hold.
30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.
Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.
21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.
19/12/2018 – AB Science provides the main achievements of this restructuring.
22/10/2018 – Final results will be available in 2019.
Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis
08/10/2018 – Results published in the Journal of Clinical Investigation Insight further strengthen the body of evidence for masitinib’s mode of action in ALS.
01/10/2018 – AB Science reports its revenues for the first half of 2018 and provides an update on its activities.
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
23/07/2018 – A trend analysis for OS was planned after a certain number of events are observed.